Transformable peptide nanoparticles inhibit the migration of N-cadherin overexpressed cancer cells

被引:0
作者
Jiaqi Fan [1 ,2 ]
Yu Fan [2 ]
Zijin Wei [1 ,2 ]
Yijing Li [2 ]
Xiangdan Li [1 ]
Lei Wang [2 ]
Hao Wang [2 ]
机构
[1] Key Laboratory of Catalysis and Energy Materials Chemistry of Ministry of Education & Hubei Key Laboratory of Catalysis and Materials Science,South-Central University for Nationalities
[2] CAS Center for Excellence in Nanoscience,CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety,National Center for Nanoscience and Technology (NCNST)
基金
中国国家自然科学基金; 国家重点研发计划;
关键词
D O I
暂无
中图分类号
TB383.1 []; R730.5 [肿瘤治疗学];
学科分类号
070205 ; 080501 ; 100214 ; 1406 ;
摘要
About 90% cancer-related mortality results from the cancer metastasis,which generally undergoes after epithelial-mesenchymal transition(EMT) process.N-Cadherin,overexpressed on cancer cell surface during EMT,can enhance the migration of cancer cells.He rein,we design and synthesize a transformable peptide BP-KLVFF-SWTLYTPSGQSK(BFS) that can block N-cadherin for inhibiting cancer migration and metastasis.The peptide BFS consists of three modules including(1) the hydrophobic bis-pyrene(BP) unit for forming and locating nanoparticles,(2) the KLVFF peptide sequence for forming and stabilizing fibrous structures and(3) the targeting peptide sequence SWTLYTPSGQSK that can specifically bind to Ncadherin.The peptide BFS can form nanoparticles in PBS,which can transform to nanofibers when targeting and binding to N-cadherin.The nanofibers inhibit the migration of N-cadherin overexpressed MDA-MB-436 cancer cells.The peptide BFS shows 83.6% inhibiting rate in cells wound healing assay.In addition,the inhibition rate is 67.9% when the BFS applied in transwell migration assay.These results indicate that the BFS has excellent ability to inhibit migration of cancer cells.This self-assembly strategy could be potentially utilized to regulate the key protein during EMT for inhibiting the tumor metastasis.
引用
收藏
页码:1787 / 1791
页数:5
相关论文
共 50 条
  • [21] N-cadherin influences migration of oligodendrocytes on astrocyte monolayers
    Schnädelbach, O
    Blaschuk, OW
    Symonds, M
    Gour, BJ
    Doherty, P
    Fawcett, JW
    MOLECULAR AND CELLULAR NEUROSCIENCE, 2000, 15 (03) : 288 - 302
  • [22] N-cadherin impedes proliferation of the multiple myeloma cancer stem cells
    Sadler, Nicole M.
    Harris, Britney R.
    Metzger, Brittany A.
    Kirshner, Julia
    AMERICAN JOURNAL OF BLOOD RESEARCH, 2013, 3 (04): : 271 - +
  • [23] Regulation of collective cell invasion of prostate cancer cells by N-cadherin
    Cui, Y.
    Blee, A.
    Yamada, S.
    MOLECULAR BIOLOGY OF THE CELL, 2011, 22
  • [24] Effect of N-cadherin activation on Matrigel invasion and collagen I migration in melanoma cells
    Choe, LA
    Baer, RW
    FASEB JOURNAL, 2006, 20 (05) : A1294 - A1294
  • [25] Roles of N-cadherin and gap junction during transendothelial migration of melanoma cells.
    Chen, N
    Voura, EB
    Siu, CH
    MOLECULAR BIOLOGY OF THE CELL, 1999, 10 : 75A - 75A
  • [26] IN VIVO PHAGE DISPLAY IDENTIFIES PEPTIDE TARGETING N-CADHERIN ON GLIOMA STEM CELLS
    Potez, Marine
    Kim, Jongmyung
    She, Chunhua
    Chaudhary, Neelkamal
    Liu, James
    NEURO-ONCOLOGY, 2020, 22 : 196 - 196
  • [27] N-cadherin: a novel target for cancer therapy?
    Kelland, Lloyd
    DRUGS OF THE FUTURE, 2007, 32 (10) : 925 - 930
  • [28] N-cadherin—a target for prostate cancer therapy
    Lisa Richards
    Nature Reviews Clinical Oncology, 2011, 8 (2) : 63 - 63
  • [29] Downregulation of N-cadherin in the neointima stimulates migration of smooth muscle cells by RhoA deactivation
    Blindt, R
    Bosserhoff, AK
    Dammers, J
    Krott, N
    Demircan, L
    Hoffmann, R
    Hanrath, P
    Weber, C
    Vogt', F
    CARDIOVASCULAR RESEARCH, 2004, 62 (01) : 212 - 222
  • [30] Transendothelial migration of prostate cancer cells is dependent on both N-cadherin and ZEB1, a repressor of the epithelial phenotype
    Drake, Justin
    Strohbehn, Garth
    Moreland, Jessica
    Henry, Michael
    CANCER RESEARCH, 2009, 69